Stock AnalizPalvella Therapeutics, Inc. PVLA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Palvella Therapeutics, Inc. (PVLA) is a healthcare company listed in the US with a market value of about $2.2B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -59%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $43M | $26M | $31M | $29M | $46M | $29M | $25M | $6M |
| Net income | -$42M | -$17M | $19M | -$33M | -$46M | -$37M | -$25M | -$27M | -$18M | -$23M |
| Free cash flow | — | — | -$14M | -$61M | -$9M | -$49M | -$55M | -$3M | $48M | -$15M |
| EPS (diluted) | $-3.71 | $-7.83 | $2.17 | $-22.90 | $-36.12 | $-34.60 | $-28.49 | $-25.44 | $-20.35 | $-27.98 |
| Net margin | — | — | 43.7% | -128.5% | -145.6% | -127.0% | -55.0% | -91.9% | -69.8% | -391.0% |
| ROIC | -82.0% | -17.4% | — | — | -79.0% | -55.8% | -40.2% | -76.3% | -100.1% | -71.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $233.80, 53% above the current price; targets range from $207.00 to $267.00; the consensus rating is “Strong buy”; expected EPS is $-5.94 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Palvella Therapeutics pay a dividend?
Not currently.
Is Palvella Therapeutics a good stock to buy?
We do not give buy or sell advice. Palvella Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.